InduPro key facts
as of Oct 2026- Operator of a biopharma company intended to manipulate protein pairings via induced protein proximity to create novel signaling pathways and logic gates.
- InduPro is valued at approximately $124.5M as of Oct 2026 (last reported valuation).
- It has raised $85.0M across 2 recorded rounds; the latest was Series B ($77.0M) in Aug 2026.
- Notable investors include The Engine, Emerson Collective, Euclidean Capital, Eli Lilly, MRL Ventures Fund — 8 tracked in total.
- Status: Privately Held (backing).
InduPro's last reported valuation, Jun 2024. Nothing priced has surfaced since.
- ·Watch InduPro: the Monday email on marks, rounds and moves
InduPro funding rounds
2 roundsInduPro leadership
- Prakash RamanChief Executive Officer
- Scott LesleyPresident & Chief Scientific Officer
- Amanda J. RedigChief Medical Officer
- Sally JohnsonChief People Officer
InduPro valuation
InduPro's last reported valuation was $125 million in Jun 2024. No priced round, secondary trade or fund mark has surfaced since.
Recent activity
In the last 90 days, InduPro's record added 1 funding round.
How much has InduPro raised?
InduPro has raised $85 million across 2 recorded rounds since 2024. The largest was an $85 million Series A in Jun 2024; the most recent was a $77 million Series B in Aug 2026.
InduPro investors
8 investors are on record for InduPro, including The Engine, Emerson Collective, Euclidean Capital and Eli Lilly.
Who runs InduPro
8 people are listed on the InduPro team: 5 executives and 2 board members, including K. Chris Garcia (Scientific Founder) and Prakash Raman (Chief Executive Officer).
Comparable companies
Comparable biotech names by valuation on PrivateMarketView: Chai Discovery ($1.3 billion), Merida Biosciences ($228 million) and Nuwacell ($203 million).
About InduPro
Operator of a biopharma company intended to manipulate protein pairings via induced protein proximity to create novel signaling pathways and logic gates. The company's platform integrates inherent protein proximity at the cell surface and translates biological insights into transformative therapeutics, enabling patients with therapies through novel cell-surface platform technologies.
- Industry
- Biotech
- Sector
- Healthcare
- HQ
- Seattle, WA, United States
- Founded
- 2022
- Employees
- 49
- Website
- induprotx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.